Co-Authors
This is a "connection" page, showing publications co-authored by SANAM LOGHAVI and WARREN C FISKUS.
Connection Strength
1.206
-
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2024 Nov 19.
Score: 0.248
-
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood. 2024 05 16; 143(20):2059-2072.
Score: 0.240
-
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023 04 13; 13(1):53.
Score: 0.222
-
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022 11; 36(11):2729-2733.
Score: 0.214
-
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer J. 2024 02 05; 14(1):25.
Score: 0.059
-
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023 Nov; 98(11):1780-1790.
Score: 0.057
-
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023 06; 37(6):1336-1348.
Score: 0.055
-
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019.
Score: 0.055
-
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
Score: 0.055